#ESMO2023 Archives - Page 2 of 2

ESMO Hot Review | Prof. Ying Fan: DB-04 Study Shows Survival Benefit and Sustained Efficacy of T-DXd Treatment

By Lisa Cui 2024.01.17

Editor's Note: The mid-term analysis results of the DESTINY-Breast04 (DB-04) study were striking, quickly influencing international guidelines such as NCCN and ESMO, and obtaining approvals for indications related to HER2…

ESMO Expert Commentary | Dr. Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

By Mourabit Halima 2024.01.17

Editor's Note: Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled…

ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

By Peng Longmei 2024.01.17

Editor's Note: HR+/HER2- is the most common subtype of breast cancer, accounting for approximately 65% to 70% of all breast cancer cases. Improving the survival benefits for patients with advanced…

ESMO 2023丨Professor Feng Jin: CLEVER Study – Repurposing Old Drugs for Targeting Dormant Tumor Cells to Prevent High-Risk Breast Cancer Recurrence

By El Bachir MOURABIT 2024.01.15

Editor's note: Previous studies have indicated a close association between disseminated tumor cells (DTC) in the bone marrow and breast cancer recurrence. At the 2023 ESMO conference, data from the…

ESMO 2023 China Voice | Professor Fei Han: Hot Research on Nasopharyngeal Carcinoma in China, Innovative Drug Efficacy Worth Expecting!

By Mourabit Halima 2024.01.15

Editor's Note: The ESMO Annual Meeting in 2023 was held grandly in Madrid, Spain, from October 20th to 24th. As an authoritative annual event in the field of oncology, the…

ESMO Exclusive Interview | Dr.Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

By Lisa Cui 2024.01.15

Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer Background The clinical outcomes of metastatic colorectal cancer (mCRC) therapies are limited. Guanylyl cyclase 2C (GCC)…

Prostate Cancer: Unveiling the Roles of Germline and Tumor Testing with Professor Kim Nguyen N. Chi

By Lisa Cui 2024.01.13

Delving into the intricate landscape of prostate cancer diagnostics, understanding the roles of germline testing and tumor testing is paramount. At the prestigious ESMO Congress 2023, Oncology Frontier had the…